Companies: 10,795·Total market cap: $144.5T
Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBANASDAQHealthcare● Active
$0.92
$-0.02(-2.12%)
Market Cap$245590198
P/E Ratio—
52W High$4.079
52W Low$0.875
Overview

Akebia Therapeutics, Inc.（AKBA）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

akba · 股价预测 · 11 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 11 位华尔街分析师

SellBuy

Buy

11 位分析师

共识

评级分布

Strong Buy
0
Buy
7
Hold
3
Sell
1
Strong Sell
0
合计: 11 · 买入占比: 63.6%

12 个月目标价

High

$4.00

Consensus

$4.00

+336.8% upside

Low

$4.00

Median: $4 · Last Close: $0.92

Akebia Therapeutics, Inc.（AKBA）的分析师共识为 Buy，基于过去 3 个月内 11 位华尔街分析师的评级。AKBA 的 12 个月平均目标价为 $4.00，相对当前价 $0.92 代表 +336.8% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

Bear

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$0.87↓ 5.00%

1-day model range: $0.86–$0.88. Peak: $0.88 (-5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$1+9.8%
2028$1+15.3%
2029$1+18.1%
2030$1+19.5%
2031—+20.3%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)40.4Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · AKBA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$0.95SELL
MA 10$0.99SELL
MA 20$1.03SELL
MA 50$1.25SELL
MA 100$1.30SELL
MA 200$1.79SELL
Current $AKBA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.95SELL
EMA 10$0.98SELL
EMA 20$1.05SELL
EMA 50$1.19SELL
EMA 100$1.36SELL
EMA 200$1.66SELL
Current $AKBA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
BTIG2026-04-07
Maintains
Buy→Buy
BTIG2026-02-25
Maintains
Buy→Buy
HC Wainwright & Co.2026-02-06
Maintains
Buy→Buy
Piper Sandler2026-02-06
Maintains
Overweight→Overweight
HC Wainwright & Co.2025-12-02
Maintains
Buy→Buy
BTIG2025-12-02
Maintains
Buy→Buy
HC Wainwright & Co.2025-10-30
Maintains
Buy→Buy
BTIG2025-10-29
Maintains
Buy→Buy
HC Wainwright & Co.2025-04-04
Maintains
Buy→Buy
Piper Sandler2025-03-14
Maintains
Overweight→Overweight

Wall Street analysts have recently issued updated ratings on Akebia Therapeutics, Inc. (AKBA) stock. Of the recent 62 rating actions, 3 were upgrades and 5 were downgrades. 11 analysts currently cover AKBA.

分析师推荐趋势

Buy ratings2 → 1↓ 1
Hold ratings0 → 0
Sell ratings0 → 0

AKBA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$207M

↑ 2.1% YoY

Revenue Next Year

$160M

↓ 22.7% YoY

EPS This Year

$-0.14

EPS Next Year

$-0.23

↑ 62.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AKBA EPS of $-0.14 for the current fiscal year, based on estimates from 3 analysts. The AKBA revenue forecast is $207M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

AKBA 股价预测由两类独立数据源支撑：来自 11 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。AKBA 的共识目标价为 $4.00（+336.8% 上行空间），分析师共识为 Buy。

AKBA 的短期预测（明日）为 $0.87（-5.00%）。 AKBA 对 2027 年的股价预测均值为 $1。 AKBA 对 2030 年的预测区间为 $1–$1。

Akebia Therapeutics, Inc. 在 NASDAQ 上市，代码 AKBA。AKBA 在 2027 年的整体展望偏积极，在覆盖分析师中约 64% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

AKBA 预测 · 8 个问题

根据 11 位华尔街分析师，AKBA 的 12 个月平均目标价为 $4.00，最高 $4.00、最低 $4.00。若有图表，中位目标价可在上方查看。相对当前价 $0.92，隐含约 +336.8% 的上行空间。

AKBA 目标价AKBA 分析师目标价AKBA 12个月目标价目标价 AKBA

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.